top of page

Free Biopharma Daily Stock Updates - 06/30/22

$XBI $74.27 | -0.71%

BiopharmIQ offers pro members full access to FDA Catalyst Calendar, PDUFA's, Biotech Stock Ideas.

Table of Contents:

Covid Updates

#HGEN -4% NIH/NIAID Locks ACTIV-5/BET-B Database. source

#VXRT -1% Vaxart Announces Agreement with hVIVO to Develop World’s First Human Omicron Challenge Model. source

Pipeline Updates

#EVFM +15% Evofem Strengthens Phexxi® Intellectual Property with New Composition of Matter Patent From USPTO. source

#HRTX -12% Heron Therapeutics Announces Restructuring and Cost Reduction Plan to Address Market Dynamics and Prepare for Long-Term Sustainability. source

#NMTR -22% 9 Meters Biopharma Announces Debt Facility to Support Phase 3 Study of Vurolenatide for Short Bowel Syndrome. source

#NMTR -22% 9 Meters Biopharma Announces Positive Preliminary Results from Phase 2 Study of Vurolenatide in Short Bowel Syndrome. source

#RPHM +14% Reneo Pharmaceuticals to Present Data from Phase 1 REN001 Limb Immobilization Study at the 17th International Congress on Neuromuscular Diseases (ICNMD 2022). source

#DARE -2% Daré Bioscience Announces Closing of Global License Agreement with Organon to Commercialize XACIATO™ (clindamycin phosphate vaginal gel, 2%), FDA-Approved Treatment for Females 12 and Older with Bacterial Vaginosis. source

#SCPH -2% scPharmaceuticals Inc. to Host FUROSCIX® (furosemide) 80mg/10mL for Subcutaneous Administration Commercial Day: An Investigational Treatment for Heart Failure Patients. source

#NRIX +2% Nurix Therapeutics Announces Clearance of Investigational New Drug Application For NX-1607 Supporting Plans to Expand Enrollment to U.S. Clinical Sites. source

#CARA -5% Cara Therapeutics Announces Positive Topline Results from KOMFORT Phase 2 Trial of Oral Difelikefalin for the Treatment of Pruritus in Patients with Notalgia Paresthetica. source

#TALS -37% Talaris Therapeutics Provides FREEDOM-1 Phase 3 Clinical Update. source

#EVAX -4% Evaxion Biotech Announces Gonorrhea as Second Bacterial Product Target. source

#CDAK -21% Codiak Provides Platform-Validating Clinical Update and Data from Phase 1 Trials of exoSTING™ and exoIL-12™. source

#ANGN -33% (6/29) Angion Announces Discontinuation of Phase 2 Trial of ANG-3070 in Patients with Primary Proteinuric Kidney Disease. source

#ENDP -11%

#BLPH -14%

#LXRX -17% (6/29) Lexicon Announces Positive Top-line Results from Phase 2 Proof-of-Concept Study of LX9211 in Painful Diabetic Neuropathy. source

#PRVB +2% Provention Bio Announces Extension of FDA User Fee Goal Date for Teplizumab to November 17, 2022. source

#AKBA -7% Akebia Therapeutics Regaining Rights to Vadadustat in the United States, Europe, China and Access Consortium Countries upon Termination of Collaboration and License Agreements with Otsuka. source


#CLDX -3% Celldex Therapeutics Presents Positive Interim Data from Barzolvolimab Phase 1b Study in Chronic Spontaneous Urticaria at EAACI 2022. source


Want to get weekly catalyst updates?

*We never spam you - unsubscribe anytime*


Business Updates

#MCRB +9% Seres Therapeutics Announces $100 Million Registered Direct Offering of Common Stock. source

#BPMC -3% Blueprint Medicines Announces Transformative $1.25 Billion Strategic Financing Collaborations with Sixth Street and Royalty Pharma. source

#VRCA -12% Verrica Announces Pricing of Public Offering of Common Stock. source

#AFMD -1.5% Affimed Establishes Scientific Advisory Board - Independent advisory panel to be made up of distinguished, key opinion leaders with scientific and clinical expertise in innate immunity and oncology.

#GERN +2% Geron Corporation Announces Expansion of Existing Loan Facility. source

#XFOR +10% X4 Pharmaceuticals Announces $55 Million Private Placement Financing and Debt Facility Amendment Extending Interest-Only Period by up to 12 Months. source


Posted by FS/DV



bottom of page